- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete...
SAN DIEGO, June 24, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination product of nanatinostat and valganciclovir has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma. Viracta's combination product candidate previously received orphan drug designations for the treatment of post-transplant lymphoproliferative disorder, plasmablastic lymphoma and angioimmunoblastic T-cell lymphoma.